Skip to main content

Table 1 Suggested dose and number of fractions per tumor site

From: Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Site

Dose (Gy)

Fractions

Lung-peripheral

45

3

Lung-central

50

5

Mediastinal/cervical lymph node

50

5

Liver

45

3

Spinal/paraspinal

30

3

Osseous

30

3

Abdominal-pelvic metastasis (lymph node/adrenal gland)

45

3